Medical devices, healthcare technology and the business of care
510(k) clearance · K261311

HYALOMATRIX

Anika Therapeutics, Inc. · Decision date Sep 2, 2026

MEDTECHLEDGER EXPLANATIONK261311

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for HYALOMATRIX, a wound dressing submitted by Anika Therapeutics, Inc., under 510(k) number K261311, with a decision date of September 2, 2026 and product code QSZ. The public database lists the classification name as Absorbable Synthetic Wound Dressing and the review panel as General & Plastic Surgery. SESE means the device was cleared as substantially equivalent to a legally marketed predicate; it is not a premarket approval.

The 510(k) summary describes the submission as an update to the packaging configuration, together with changes to the finished device: dimensional specifications and removal of the silicone layer. The device is described as a sterile, single-use non-woven pad composed of HYAFF-11, a benzyl ester of hyaluronic acid. The summary names HYALOMATRIX under K073251, cleared December 14, 2007, as the predicate and states that no clinical study was required. The source does not resolve the discrepancy between the database receipt date of 04/21/2026 and the August 6, 2026 dates in the summary, and the specialty field is recorded as Unknown.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Unknown
Decision date
Sep 2, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261311
Regulatory pathway
510(k) premarket notification
Product code
QSZ
Decision code
SESE
Decision date
Sep 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Absorbable Synthetic Wound Dressing.

Product code
QSZ
FDA device class
U

FDA decision timeline

  1. K261311 received

    Application receipt date recorded by FDA.

  2. K261311 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QSZ

Product / regulatory recordCompanyPathwayDecision dateSource
RestrataK261245
Acera Surgical, Inc.510(k) clearanceOct 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Anika Therapeutics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Beford, MA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records